维利西呱片是强心药吗？

Vericiguat is a cardiotonic drug. Vericiguat can improve the function of myocardium and blood vessels, enable the damaged heart to re-pump blood, relax blood vessels, reduce heartbeat resistance, thereby strengthening the heart.

Vericiguat can increase intracellular CGMP levels, relax smooth muscles and dilate blood vessels. It can also inhibit vasoconstriction, improve myocardial remodeling, and improve heart failure symptoms and quality of life. It is recommended for patients with heart failure with reduced ejection fraction.

Vericigua tablets

It is the first oral soluble guanylate cyclase (sGC) stimulator approved for the treatment of adults with symptomatic chronic heart failure (HFrEF) with reduced ejection fraction.

Vericiguat was approved by the FDA in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45% who are hospitalized for heart failure or require outpatient IV diuretics.

In the Phase III VICTORIA trial, in adult patients with chronic HFrEF, adding vericiguat to standard of care (SOC) compared with standard of care (SOC) adding placebo was associated with a significant reduction in the risk of the primary composite endpoint of death from cardiovascular (CV) causes or first hospitalization for heart failure (HHF).

Vericiguat for the treatment of heart failure

The VICTORIA phase clinical trial showed that the composite primary outcome of death or first hospitalization from cardiovascular causes was lower in the veliciguat group than in the placebo group. The overall number of hospitalizations for heart failure was significantly reduced in the veliciguat group compared with the placebo group. The composite secondary outcome of death from any cause or first heart failure hospitalization was significantly reduced in the veliciguat group.

Veliciguat is safe and effective in reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and reduced EF.

Other drugs to treat heart failure

1. Angiotensin-converting enzyme inhibitors: such as captopril, enalapril, perindopril, etc., have the effect of dilating blood vessels and improving hemodynamics. Early and adequate application can relieve symptoms, delay the progression of heart failure, and reduce mortality.

2. Aldosterone receptor blockers: can inhibit cardiovascular remodeling and improve the long-term prognosis of heart failure. Commonly used drugs include spironolactone, eplerenone, etc.

3. Sodium-glucose cotransporter 2 inhibitors: such as empagliflozin and dapagliflozin, can reduce cardiovascular death or hospitalization for heart failure and all-cause death in patients with HFrEF.

4. Beta blockers: such as metoprolol, bisoprolol, etc.

Recommended related articles: